HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MEN WITH PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY USING REAL-WORLD DATA
Author(s)
Michele R. Cole, MS, PharmD1, Andrew W. Hahn, MD2, Efstratios Koutroumpakis, MD2, Abhishek Kavati, PhD3, Randala Hamdan, PhD3, Brenna Brady, PhD4, CASSANDRA LICKERT, MD5;
1Myovant, Director, Medical Managed Markets Access, Marlborough, MA, USA, 2The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, Houston, TX, USA, 3Pfizer Inc., New York, NY, USA, 4Merative, Ann Arbor, MI, USA, 5Sumitomo Pharma America, Inc., Marlborough, MA, USA
1Myovant, Director, Medical Managed Markets Access, Marlborough, MA, USA, 2The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, Houston, TX, USA, 3Pfizer Inc., New York, NY, USA, 4Merative, Ann Arbor, MI, USA, 5Sumitomo Pharma America, Inc., Marlborough, MA, USA
OBJECTIVES: Prostate cancer (PC) is associated with significant economic and clinical burden. Androgen deprivation therapy (ADT) is the cornerstone of treatment for PC. However, impact of ADT on healthcare resource utilization (HCRU) and costs in real-world settings remains uncertain.
METHODS: Using the MerativeTM MarketScan® Commercial and Medicare Databases, men with PC who initiated ADT (Jan 2018-May 2024) were identified. Index date was the first ADT claim; men had continuous enrollment ≥12 months before and ≥2 months after index. All-cause preindex and postindex HCRU and costs were analyzed and presented as per-patient-per-month (PPPM) to address the variable follow-up period.
RESULTS: Among 17,336 patients (mean age 69±10 y), 90.4% received gonadotropin hormone-releasing hormone (GnRH) agonists and 9.6% received GnRH antagonists (3.6% relugolix). Preindex, patients had a mean (SD) PPPM of 0.02 (0.04) inpatient admissions and 0.04 (0.09) emergency room (ER) visits; there were no meaningful differences between GnRH agonist and antagonist initiators. Men with baseline cardiovascular disease (CVD) had more inpatient admissions and ER visits than men without baseline CVD (mean [SD], 0.05 [0.07] and 0.08 [0.12] vs 0.01 [0.04] and 0.03 [0.08], respectively). Postindex, the overall patient population had a mean (SD) PPPM of 0.02 (0.09) inpatient and 0.05 (0.16) ER services; HCRU was similar in agonist and antagonist initiators. Men with baseline CVD continued to have the highest mean (SD) HCRU (inpatient, 0.04 [0.12]; ER, 0.08 [0.21]). Nearly all patients received outpatient services, which accounted for ~75% of total cost in the postindex period; outpatient pharmacy and inpatient costs accounted for ~20% and ~7%, respectively.
CONCLUSIONS: While use of inpatient and ER services was similar in GnRH agonist and antagonist initiators, men with baseline CVD had higher HCRU than those without. Careful selection of ADT and management of baseline CVD may decrease HCRU for men treated for PC.
METHODS: Using the MerativeTM MarketScan® Commercial and Medicare Databases, men with PC who initiated ADT (Jan 2018-May 2024) were identified. Index date was the first ADT claim; men had continuous enrollment ≥12 months before and ≥2 months after index. All-cause preindex and postindex HCRU and costs were analyzed and presented as per-patient-per-month (PPPM) to address the variable follow-up period.
RESULTS: Among 17,336 patients (mean age 69±10 y), 90.4% received gonadotropin hormone-releasing hormone (GnRH) agonists and 9.6% received GnRH antagonists (3.6% relugolix). Preindex, patients had a mean (SD) PPPM of 0.02 (0.04) inpatient admissions and 0.04 (0.09) emergency room (ER) visits; there were no meaningful differences between GnRH agonist and antagonist initiators. Men with baseline cardiovascular disease (CVD) had more inpatient admissions and ER visits than men without baseline CVD (mean [SD], 0.05 [0.07] and 0.08 [0.12] vs 0.01 [0.04] and 0.03 [0.08], respectively). Postindex, the overall patient population had a mean (SD) PPPM of 0.02 (0.09) inpatient and 0.05 (0.16) ER services; HCRU was similar in agonist and antagonist initiators. Men with baseline CVD continued to have the highest mean (SD) HCRU (inpatient, 0.04 [0.12]; ER, 0.08 [0.21]). Nearly all patients received outpatient services, which accounted for ~75% of total cost in the postindex period; outpatient pharmacy and inpatient costs accounted for ~20% and ~7%, respectively.
CONCLUSIONS: While use of inpatient and ER services was similar in GnRH agonist and antagonist initiators, men with baseline CVD had higher HCRU than those without. Careful selection of ADT and management of baseline CVD may decrease HCRU for men treated for PC.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE52
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Oncology